SecBot SecBot
SECBOTREPLAY Home › Report › CYTK

CYTK · Cytokinetics presented new data at ESC Heart Failure 2026 reinforcing…

Cytokinetics, Incorporated · PRESS-RELEASE filed May 11, 2026 at 10:06 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed May 11, 2026 at 10:06 ET

Cytokinetics presented new data at ESC Heart Failure 2026 reinforcing the clinical profile of MYQORZO (aficamten) in obstructive HCM, including superiority over metoprolol in MAPLE-HCM, long-term safety in FOREST-HCM, and favorable left atrial remodeling in SEQUOIA-HCM. The press release is a routine scientific update with no new regulatory or financial catalysts, and the stock impact is likely muted given the absence of material commercial or regulatory news.

  • MAPLE-HCM showed aficamten significantly improved exercise capacity, outflow gradients, and NT-proBNP across all doses, while metoprolol showed no improvement.
  • FOREST-HCM open-label extension data (up to 96 weeks) showed no increase in arrhythmias, including NSVT or atrial fibrillation, with aficamten.
  • SEQUOIA-HCM analysis showed aficamten significantly improved left atrial reservoir strain (+2.9%; p=0.004) and conduit strain (+2.2%; p=0.001) vs placebo.
  • Real-world evidence from 273 patients showed 26.6% activity impairment due to oHCM, with higher impairment in obstructive vs non-obstructive HCM (30.2% vs 19.2%; p=0.0003).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access